Comparison of clinical and pharmacokinetic parameters of dasatinib in patients with and without a T315I mutation: (A) plasma concentration 2 h after dasatinib administration (C
), (B) maximum plasma concentration after dasatinib administration (C
), and (C) area under the plasma concentration-time curve from 0 to 4 h (AUC
). Boxes represent interquartile ranges (IQR) with the median represented by bold horizontal lines. The ends of the whiskers (vertical lines) represent the smallest and largest values that are not outliers.